Trial Profile
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Ascending Dose Levels of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Oct 2019
Price :
$35
*
At a glance
- Drugs Staphylococcus aureus vaccine (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Pfizer
- 01 Oct 2019 Results assessing taphylococcus aureus colonization published in the Journal of Infection.
- 12 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2011 Results were presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 27th International Congress of Chemotherapy (ICC).